Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2– breast cancer (LEADER) by Laura M. Spring, Lauren Scarpetti, Arielle J. Medford, Andrzej Niemierko, Amy Comander, Therese Mulvey, Lowell Schnipper, Steven J. Isakoff, Beverly Moy, Seth A. Wander, Jennifer Shin, Zanta Ephrem, Anneke R. Laposta, Elyssa Denault, Elizabeth Abraham, Gayle Calistro, Ekaterina Kalashnikova, Angel Rodriguez, Minetta C. Liu, Alexey Aleshin, Jeffrey Peppercorn, Leif W. Ellisen, Aditya Bardia

Get full text